Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessNeuroPace - About the company
NeuroPace is a public company based in Mountain View (United States), founded in 1997. It operates as a Developer of implantable neurostimulation system for epilepsy treatment. NeuroPace has raised $264M in funding from investors like New Enterprise Associates, Technology Partners and InterWest Partners. The company has 19 active competitors, including 4 funded and 4 that have exited. Its top competitors include companies like Cyberonics, Engage Therapeutics and Cadence Neuroscience.
Company Details
Developer of implantable neurostimulation system for epilepsy treatment. The system delivers personalized treatment by responding to abnormal brain activity and provides EEG data to improve patient care. It offers a potential solution for adults with drug-resistant focal epilepsy, aiming to reduce seizures and manage quality of life. The device is intended for patients with localized seizure foci and requires prior diagnostic testing. The company also provides resources and support for patients and healthcare providers.
Key Metrics
Founded Year
1997
Location
Mountain View, United States
Stage
Public
Total Funding
$264M in 6 rounds
Latest Funding Round
Investors
Ranked
1st among 19 active competitors
Annual Revenue
$45.5M as on Dec 31, 2022
Employee Count
184 as on Dec 31, 2024
Similar Companies
Exit Details
Public
Legal entities associated with NeuroPace
NeuroPace is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Aug 29, 2011 | $45.5M (as on Dec 31, 2022) | - | - | |
Dec 26, 999 | - | 184 (as on Dec 31, 2024) | - |
Get your free copy of NeuroPace's company profile
NeuroPace's funding and investors
Filter this listNeuroPace has raised a total funding of $264M over 6 rounds. Its first funding round was on 2005. Its latest funding round was a Series E round on Aug 19, 2020 for $69.4M. 4 investors participated in its latest round, lead by Accelmed.
NeuroPace has 15 institutional investors including New Enterprise Associates, Technology Partners and InterWest Partners.
Here is the list of recent funding rounds of NeuroPace:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Aug 19, 2020 | $69.4M | Series E | 4986043 | 5009205 | |
Sep 21, 2016 | $74M | Series E | 4351807 | 8101595 | |
Jul 01, 2013 | $18.1M | Series D | 4302079 | 8176476 | - |
Access funding benchmarks and valuations. Sign up today!View details of NeuroPace's funding rounds and investors
NeuroPace's founders and board of directors
Founder? Claim ProfileNeuroPace's employee count trend
NeuroPace has 184 employees as of Dec 24. The total employee count is 8.0% more than what it was in Dec 23. Here is NeuroPace's employee count trend over the years:Uncover NeuroPace's growth story! Sign up today!Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
NeuroPace's Competitors and alternates
Top competitors of NeuroPace include Cyberonics, Engage Therapeutics and Cadence Neuroscience. Here is the list of Top 10 competitors of NeuroPace, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | NeuroPace 1997, Mountain View (United States), Public | Developer of implantable neurostimulation system for epilepsy treatment | $264M | 61/100 | |
2nd | Cyberonics 1987, Houston (United States), Public | Vagus nerve stimulation device for epilepsy and treatment resistant depression | - | - | 39/100 |
3rd | Engage Therapeutics 2017, Summit (United States), Acquired | Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures | $30.6M | 38/100 | |
4th | Cadence Neuroscience 2016, Redmond (United States), Series B | Developer of medical devices for treating neurological disorders | $41M | 36/100 | |
5th | NightWatch 2013, Leiden (Netherlands), Series A | Provider of wearable device for epilepsy seizure detection during sleep | - | 25/100 | |
6th | A medical device company which engages in developing neuro therapy solutions. | $2.6M | 23/100 | ||
7th | Portfolio of devices and tools for neurological surgery | - | 22/100 | ||
8th | Neurolink 2007, San Antonio (United States), Deadpooled | Drug-device combination for epilepsy | $3.88M | 21/100 | |
9th | OceansBIo 2021, Changwon (South Korea), Public | Developer of electroceutical devices for epilepsy treatment | - | 20/100 | |
10th | Developer of light-based surgical tools for tumor and epilepsy treatments | - | - | 20/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on NeuroPace's competitors? Click here to see the top ones
NeuroPace's Investments and acquisitions
NeuroPace has made no investments or acquisitions yet.
Reports related to NeuroPace
Here is the latest report on NeuroPace's sector:
News related to NeuroPace
Filter this listMedia has covered NeuroPace for a total of 20 events in the last 1 year, 9 of them have been about company updates and 1 about people movement.
•
Two Sigma Investments LP Makes New Investment in NeuroPace, Inc. (NASDAQ:NPCE)MarketBeat•Jun 11, 2025•Two Sigma Investments, NeuroPace
•
NeuroPace Secures Up to $75 Million in Debt Financingaktiencheck.de AG•Jun 05, 2025•NeuroPace, MidCap Financial, CRG
•
Pomerantz Law Firm Investigates NeuroPace, Inc. (NPCE) on Behalf of InvestorsGlobeNewswire•Jun 02, 2025•NeuroPace, Pomerantz
•
100,095 NeuroPace, Inc. Shares Acquired by Jane Street Group LLCMarketBeat•May 24, 2025•NeuroPace, Jane Street
•
•
Walleye Capital LLC Purchases Shares of 28,547 NeuroPace, Inc. (NASDAQ:NPCE)MarketBeat•Apr 27, 2025•NeuroPace
•
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingGlobeNewswire•Apr 08, 2025•NeuroPace
•
NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidanceSeeking Alpha•Apr 02, 2025•NeuroPace
•
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire•Mar 05, 2025•NeuroPace
•
NeuroPace GAAP EPS of -$0.18 beats by $0.04, revenue of $21.47M beats by $0.33MSeeking Alpha•Mar 04, 2025•NeuroPace
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about NeuroPace
Explore our recently published companies
- Verbeeminstallaties.nl - Netherlands based, Unfunded company
- Tamiya - Shizuoka based, 1946 founded, Unfunded company
- Stratiom - Winchester based, 2025 founded, Unfunded company